Prucalopride is a medication designed to treat chronic constipation – a health problem characterized by infrequent and difficult passage of stools over a prolonged period, along with a range of other distressing symptoms such as abdominal bloating, flatulence, and even vomiting.
Traditional treatment options for chronic constipation involve mostly diet and lifestyle changes and/or laxatives. 1
USA: Motegrity Europe: Resolor Canada: Resotran
The medicine can only be obtained with a prescription.
Motegrity MOTEGRITY (prucalopride succinate – tablet;oral) Manufacturer: SHIRE DEV LLC Approval date: December 14, 2018 Strength(s): EQ 1MG BASE [RLD], EQ 2MG BASE [RLD]
The cost for Motegrity oral tablet 1 mg in the USA at the time this article was written is around $465 for a supply of 30 tablets, depending on the pharmacy you visit.
Prices are for cash paying customers and may not be valid with insurance plans.
On December 7, 2011, Health Canada issued a Notice of Compliance to Janssen Inc. for the drug product, Resotran™.
Resotran™ contains the medicinal ingredient prucalopride, as prucalopride succinate, which is an enterokinetic agent.
Resolor was first approved in Europe in 2009 for symptomatic treatment of chronic constipation in women and in 2015 in men in whom laxatives fail to provide adequate relief.